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Abstract Anticoagulant therapy is recommended for
the secondary prevention of stroke in patients with atrial
fibrillation (AF). The identification of patients at high
risk for early recurrence, which are potential candidates
to prompt anticoagulation, is crucial to justify the risk of
bleeding associated with early anticoagulant treatment.
The aim of this study was to evaluate in patients with
acute ischemic stroke and AF the association between
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findings at trans-thoracic echocardiography (TTE) and
90 days recurrence. In consecutive patients with acute
ischemic stroke and AF, TTE was performed within
7 days from hospital admission. Study outcomes were
recurrent ischemic cerebrovascular events (stroke or
TIA) and systemic embolism. 854 patients (mean age
76.3 ± 9.5 years) underwent a TTE evaluation; 63
patients (7.4 %) had at least a study outcome event. Left
atrial thrombosis was present in 11 patients (1.3 %)
among whom 1 had recurrent ischemic event. Left atrial
enlargement was present in 548 patients (64.2 %) among
whom 51 (9.3 %) had recurrent ischemic events. The
recurrence rate in the 197 patients with severe left atrial
enlargement was 11.7 %. On multivariate analysis, the
presence of atrial enlargement (OR 2.13; 95 % CI
1.06–4.29, p = 0.033) and CHA2DS2-VASc score (OR
1.22; 95 % CI 1.04–1.45, p = 0.018, for each point
increase) were correlated with ischemic recurrences. In
patients with AF-associated acute stroke, left atrial
enlargement is an independent marker of recurrent stroke
and systemic embolism. The risk of recurrence is
accounted for by severe atrial enlargement. TTE-de-
tected left atrial thrombosis is relatively uncommon.
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Background
Atrial fibrillation (AF) is the most common cardiac
arrhythmia and is associated with an elevated risk of
ischemic stroke and systemic thromboembolism. After
an acute stroke, patients with AF have a high risk of
early recurrence that is about 8 % within 90 days from
the acute event [1].
Anticoagulant therapy is effective for the secondary
prevention of stroke in patients with AF. The balance
between the risk of recurrence and bleeding associated
with anticoagulant therapy for any given patient
remains unclear. The identification of patients at high
risk for early recurrence, which are potential candidates
to prompt anticoagulation, is crucial to justify the risk
of bleeding associated with early anticoagulant
treatment.
Echocardiography, transthoracic (TTE) or less com-
monly transesophageal (TEE), is included in the work-up
of patients with AF and stroke. In these patients,
echocardiography detected left atrial thrombosis supports
early anticoagulation [2]. Likewise, in patients with acute
stroke, left atrial enlargement has been associated with the
risk of stroke recurrence [3].
The aim of this study was to evaluate the potential
association between TTE findings in the early stage of
cerebral ischemia (within 7 days from hospital admission)
and the risk of 90-day thromboembolic recurrence in
patients with acute ischemic stroke and AF.
Methods
Patients
Data for this analysis were extracted from the database of a
prospective multicentre study which enrolled consecutive
patients with acute stroke and AF (the RAF study) [1]. This
study, carried out between January 2012 and March 2014,
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enrolled 1029 consecutive patients in 29 Stroke Units from
Europe and Asia.
On admission, the severity of acute stroke was assessed
using the National Institutes of Health Stroke Scale
(NIHSS); all investigators were certified about the use of
this scale.
AF was classified as paroxysmal (episodes terminating
spontaneously within 7 days), persistent (episodes lasting
more than 7 days requiring pharmacologic and/or electrical
stimulation), or permanent (persisting for more than 1 year,
either because cardioversion failed or was not attempted).
Risk factors
Data on known stroke risk factors were collected as
reported in the main paper [1].
A cerebral computed tomography (CT) or magnetic
resonance (MR) was performed on admission in all patients
to exclude intracranial hemorrhage. A second cerebral CT
scan or MR was performed 48–72 h from stroke onset. The
sites and sizes of the qualifying infarcts were determined
based on standard templates [4, 5] as follows: (a) small,
when a lesion was B1.5 cm in the anterior or posterior
circulation, (b) medium, when a lesion was in a cortical
superficial branch of middle cerebral artery (MCA), in the
MCA deep branch, in the internal border zone territories, in
a cortical superficial branch of posterior cerebral artery
(PCA), in the PCA branch or in a cortical superficial branch
of the anterior cerebral artery (ACA), (c) large anterior,
when a lesion involved the complete territory of MCA,
PCA, or ACA, in two cortical superficial branches of
MCA, in a cortical superficial branch of MCA associated to
the MCA deep branch, or in more than one artery territory
(e.g., MCA associated to ACA territories), (d) large
posterior, when a lesion was C1.5 cm in the brain stem or
cerebellum [6].
Echocardiogram evaluation
TTE was performed within 7 days form stroke onset by a
local cardiologist using a standardized protocol. Patients
were imaged in the left lateral decubitus. Images were
obtained using a 3.5 MHz transducer, at a depth of 16 cm
in the parasternal (standard long- and short-axis images)
and apical views (standard long-axis, two- and four-
chamber images). Standard two-dimensional and color
Doppler data, triggered to the QRS complex, were saved in
cine loop format. Pulsed and continuous wave Doppler data
were also stored digitally.
TTE analysis included the presence of: (1) intra-cardiac
thrombus; (2) left atrial enlargement; (3) mitral valve
stenosis or regurgitation; (4) aortic valve stenosis or
regurgitation; (5) tricuspidal valve stenosis or regurgita-
tion; (6) dilated cardiomyopathy with left ventricular
ejection B40 %. The presence of pacemaker, biological or
mechanical valve (mitral or aortic) was also assessed.
The presence of an intra-cardiac thrombus was diag-
nosed by the presence of an echo-dense mass distinct from
the endocardium in any cardiac cavity [7].
Left atrial enlargement was defined following the
American Society of Echocardiography guidelines mea-
suring the left atrial diameter or volume taking into account
the difference between sexes [8]. The severity of atrial
enlargement was defined according the definitions descri-
bed in Table 1.
Mitral, aortic and tricuspid stenoses or regurgitations were
dichotomized as absent or present (mild/moderate/severe)
following the definitions of published guidelines [9, 10].
Table 1 Definitions of left atrial enlargement according to the severity [8]
Women Men
Reference
Range
Mildly
abnormal
Moderately
abnormal
Severely
abnormal
Reference
Range
Mildly
abnormal
Moderately
abnormal
Severely
abnormal
Atrial dimension
LA diameter, cm 2.7–3.8 3.9–4.2 4.3–4.6 C4.7 3.0–4.0 4.1–4.6 4.7–5.2 C5.2
LA diameter/
BSA, cm/m2
1.5–2.3 2.4–2.6 2.7–2.9 C3.0 1.5–2.3 2.4–2.6 2.7–2.9 C3.0
Atrial area
LA area, cm2 B20 20–30 30–40 [40 B20 20–30 30–40 [40
Atrial volumes
LA volume, mL 22–52 53–62 63–72 C73 18–58 59–68 69–78 C79
LA volume/BSA,
mL/m2
22 ± 6 29–33 34–39 C40 22 ± 6 29–33 34–39 C40
LA left atrial, BSA body surface area in m2
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Evaluation of outcome
Patients were followed-up prospectively by office or tele-
phone interviews. Study outcome was the composite of
recurrent ischemic cerebrovascular events (stroke or TIA)
and symptomatic systemic embolisms. Recurrent ischemic
stroke was defined as the sudden onset of a new focal
neurological deficit of vascular origin in a site consistent
with the territory of a major cerebral artery and after
exclusion of cerebral hemorrhage at neuroimaging. TIA
was defined as a transient episode of neurological dys-
function caused by focal brain ischemia without acute
infarction. Systemic embolism was defined as an acute
vascular occlusion of an extremity or organ confirmed by
imaging, surgery, or autopsy. The diagnosis of systemic
embolism was independently adjudicated by vascular
surgeons.
Statistical analysis
Differences in the characteristics of patients with or with-
out outcome events were tested using v-square test. Cor-
relations between TTE characteristics and risk of recurrent
Table 2 Characteristics of the patients with or without TTE evaluation
Total (n = 1029) With TTE (n = 854) Without TTE (n = 175) p
Age (mean, years) 77.2 ± 9.5 76.3 ± 9.5 81.4 ± 8.4 0.0001
NHISS (mean) 9.2 ± 7.3 8.9 ± 7.0 10.7 ± 9.0 0.002
Sex male 468 (45.5 %) 398 (46.6 %) 70 (40.0 %) 0.1
Diabetes mellitus 264 (25.6 %) 221 (26.0 %) 43 (24.8 %) 0.7
Statins 260 (25.3 %) 213 (25.2 %) 47 (27.3 %) 0.5
Hipertension 821 (79.8 %) 676 (79.8 %) 145 (83.8 %) 0.2
Hyperlipidemia 332 (32.3 %) 282 (33.4 %) 50 (29.2 %) 0.3
History stroke/TIAa 266 (25.8 %) 205 (24.3 %) 61 (35.5 %) 0.04
Smoking 190 (18.5 %) 158 (18.7 %) 32 (18.5 %) 0.5
Alcoholism 68 (6.6 %) 57 (6.7 %) 11 (6.4 %) 1.0
History of CHFb 193 (18.7 %) 167 (19.6 %) 26 (15.0 %) 0.2
History of MIc 166 (16.1 %) 142 (16.8) 24 (13.9 %) 0.4
Paroxysmal AF 364 (35.4 %) 316 (37.0 %) 48 (27.9 %) 0.023
Permanent AF 473 (46.0 %) 385 (45.1 %) 88 (51.2 %) 0.1
Persistent AF 191 (18.6 %) 155 (18.2 %) 36 (20.9 %) 0.3
Pacemaker 85 (8.3 %) 70 (8.2 %) 15 (8.7 %) 0.8
rtPA 184 (17.9 %) 158 (18.5 %) 26 (15.1 %) 0.3
Intra-arterial revascularization 46 (4.5 %) 43 (5.1 %) 3 (1.7 %) 0.067
CHA2DS2-VASc
0 17 (1.6 %) 16 (1.9 %) 1 (0.6 %) 0.053
1 54 (5.2 %) 51 (6.0 %) 3 (1.7 %)
2 91 (8.8 %) 82 (9.6 %) 9 (5.1 %)
3 200 (19.4 %) 167 (19.5 %) 33 (18.9 %)
4 243 (23.6 %) 203 (23.8 %) 40 (22.9 %)
5 206 (20.0 %) 161 (18.8 %) 45 (25.7 %)
6 129 (12.5 %) 104 (12.2 %) 25 (14.3 %)
7 66 (6.4 %) 51 (6.0 %) 15 (8.6 %)
8–9 23 (2.2) 19 (2.2 %) 4 (2.3 %)
Therapy with anticoagulants after index stroke 766 (74.4 %) 673 (78.8 %) 93 (53.1 %) 0.0001
Recurrent ischemic eventd 77 (7.6 %) 63 (7.4 %) 14 (8.0 %) 0.7
Disability at 90 days (mRS C3) 510 (49.5 %) 403 (47.6 %) 107 (61.8 %) 0.001
a Transient Ischemic attack
b Congestive heart failure
c Myocardial infarction
d Stroke/TIA/systemic embolism
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ischemic events were sought by multiple logistic regression
analysis. The variables included in the model other than the
TTE characteristics were the type of AF, CHA2DS2-VASc
score, cardiovascular risk factors, reperfusion therapy, the
severity of stroke on admission according to NIHSS score,
the presence of pacemaker, biological or mechanical valve,
anti-thrombotic treatment and size of the lesion.
The relationship between the recurrent ischemic events
and the TTE characteristics, correlated to outcome on mul-
tivariate analysis, were also explored with Cox proportional
hazard models. The Cox model provides an estimate of the
effect of TTE characteristics on recurrent ischemic events
after adjusting for: lesion sizes, age, sex, type of AF, NIHSS
on admission, anticoagulant treatment, the presence of
pacemaker and the histories of hypertension, diabetes, pre-
vious stroke/TIA and congestive heart failure.
Results
Overall, 1037 consecutive patients were included in the
study. Of these, 8 patients were excluded for incomplete
data while 1029 patients were included in the analysis; of
these, 854 patients had a TTE evaluation. The 175 patients
did not undergo TTE evaluation for the following reasons:
34 (19.4 %) early death, 86 (49.2 %) severe stroke and 55
(31.4 %) for unknown reasons. The characteristics of the
patients with and without TTE evaluation are summarized
in Table 2. Patients without TTE evaluation were older,
with a more severe stroke and with more cardiovascular
risk factors.
Mitral valve disease was present in 360 patients
(42.2 %; 275 regurgitations and 85 stenosis) while aortic
valve disease was present in 230 patients (24.9 %; regur-
gitation in 47 and stenosis in 183). In 168 patients
(19.7 %), mitral valve disease was associated with aortic
valve disease. Intra-cardiac thrombosis, all in left atrium,
was present in 11 patients (1.3 %) while atrial enlargement
was present in 548 patients (64.2 %). Atrial enlargement as
mild in 145 patients (16.9 %), moderate in 203 patients
(23.8 %) and severe in 197 (23.1 %).
Within 90 days, 63 patients (7.4 %) of those who
underwent TTE had at least a study outcome event: 49
recurrent ischemic stroke, 8 TIA and 6 symptomatic sys-
temic embolism. Three patients had two study outcome
events. The TTE characteristics of the patients with and
without outcome event are summarized in Table 3. Atrial
enlargement was present in 81 % of the patients with
recurrent ischemic events. The risk of outcome event
increased with the severity of atrial enlargement (p for
Table 3 TTE characteristics in patients with and without outcome event
Total (n = 854) Without outcome
event (n = 791)
With outcome
event (n = 63)
p
Atrial enlargement 548 (64.2 %) 497 (62.8 %) 51 (81.0 %) 0.004
Mild 145 (16.9 %) 133 (16.9 %) 12 (19.0 %) 0.6
Moderate 203 (23.8 %) 187 (23.7 %) 16 (25.4) 0.7
Severe 197 (23.1 %) 174 (22.0 %) 23 (36.5 %) 0.013
Intracardiac thrombus 11 (1.3 %) 10 (1.3 %) 1 (1.6 %) 0.5
Cardiomyopathya 99 (11.6 %) 89 (11.3 %) 10 (15.9) 0.3
Mitral disease 360 (42.2 %) 323 (40.1 %) 37 (58.7 %) 0.021
Aortic disease 230 (26.9 %) 205 (25.9 %) 25 (39.7 %) 0.026
Tricuspidal disease 213 (24.9 %) 189 (23.9 %) 24 (38.1 %) 0.016
Biological aortic valve 10 (1.2 %) 10 (1.2 %) 0 1.0
Mechanical aortic valve 17 (2.0 %) 15 (1.8 %) 2 (3.0 %) 0.3
Biological mitral valve 7 (0.8 %) 7 (0.8 %) 0 1.0
Mechanical mitral valve 23 (2.7 %) 20 (2.4 %) 3 (4.5 %) 0.2
a Left ventricular ejection B40 %
Fig. 1 The risk of an ischemic outcome event according to the
severity of atrial enlargement (p for trend 0.012)
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trend: 0.012) (Fig. 1). The recurrence rate in the 197
patients with severe left atrial enlargement was 11.7 %.
Therapy with anticoagulants after the index stroke event
was performed in 80.5 % of the patients without atrial
enlargement, in 79.3 % with mild atrial enlargement, in
77.6 % with moderate atrial enlargement and in 77.1 % of
the patients with severe atrial enlargement (p for trend
0.78).
On multivariate analysis, the presence of atrial
enlargement (OR 2.13; 95 % CI 1.06–4.29, p = 0.033) and
CHA2DS2-VASc score (OR 1.22; 95 % CI 1.04–1.45,
p = 0.018, for each point increase) were correlated with
ischemic recurrent event. Small ischemic lesion was
inversely correlated with ischemic recurrent event (OR
0.55; 95 % CI 0.30–1.00, p = 0.05). The presence of
pacemaker showed an OR 2.10; 95 % CI 0.97–4.60,
p = 0.06. When in the model the variable atrial enlarge-
ment was introduced as mild, moderate or severe, only the
presence of severe atrial enlargement was correlated with
an outcome event (OR 2.05; 95 % CI 1.08–2.87,
p = 0.027). All the remaining TTE characteristics were not
correlated with outcome event.
Figure 2 shows the adjusted analysis using the Cox
regression model that evidences the different risk for an
ischemic outcome event according to the severity of atrial
enlargement within 90 days. This analysis was adjusted for
age, sex, CHA2DS2-VASc score, lesion size, anticoagulant
therapy and NIHSS score on admission.
Discussion
In this prospective study in patients with acute stroke and
AF, TTE showed a left atrial thrombus in about 1 % and an
atrial enlargement in 65 % of the patients. The presence of
atrial enlargement was associated with a higher risk of an
ischemic recurrence within 90 days. This association was
accounted for by severe atrial enlargement.
In clinical practice, for the fear of an early recurrence, TTE
is usually performed in acute phase of stroke to detect a
thrombus and to start anticoagulant therapy earlier. This study
showed the futility of acute TTE for detection of intra-cardiac
thrombosis. About 17 % of the patients did not undergo TTE
in the acute phase of stroke and these patients were older and
withmore severe neurological deficit. Therefore, it is possible
that in these patients, the rate of intra-cardiac thrombus was
higher. However, these are not the typical patients in whom
anticoagulation would be started promptly.
Several studies demonstrated that TEE is superior to TTE
for identification of a cardiac embolic source in patients with
TIA or stroke [11, 12]. De Brujn et al. [11], in patients with
acute stroke, found a thrombus in 17 % of the patients using
TEE compared to 2 %using TTE. Thus, in patients with acute
stroke and AF, TEE is probably more useful to detect intra-
cardiac thrombosis. However, this examination in patients
with acute stroke is not easy.
Our study showed that atrial enlargement, especially
severe, was independently associated with early stroke
Fig. 2 The cumulative risk of
an ischemic outcome event
according to the severity of
atrial enlargement using Cox
regression model
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recurrence. Several studies found thatmoderate to severe left
atrial enlargement is an independent marker of recurrent
stroke of embolic subtypes in patients with ischemic stroke
even in patientswithout evidence ofAF [3, 13]. Furthermore,
atrial dilatation is correlated with more severe stroke [14].
An association between ischemic recurrent events and
the presence of a valve prosthesis, biological or mechani-
cal, was not found but the number of patients with valve
prosthesis was low (17 patients with biological prosthesis
and 40 with mechanical prosthesis).
This study has several limitations and strengths. The
evaluation of TTE and the adjudication of the outcome events
werenot centralized.Not all thepatients hadTTEexamination
and this might have introduced some selection bias.
The strengths of our study include the prospective and
multicentre design with an adequate sample size of consecu-
tive patients, making the results robust and generalizable.
Furthermore, we collected data on a wide range of potentially
confounding risk factors, allowing us to estimate the inde-
pendent effects of TTE characteristics evaluated.
In summary, in patients with AF-associated acute stroke,
atrial enlargement is an independent marker of recurrent
stroke and systemic embolism. Left atrial thrombosis is
relatively uncommon. Future studies are needed to evaluate
whether left atrial enlargement could be used to drive
prompt anticoagulant therapy in patients with acute stroke
and AF to reduce the risk of recurrence.
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